Edition:
United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

104.53USD
30 Sep 2016
Change (% chg)

$1.76 (+1.71%)
Prev Close
$102.77
Open
$103.42
Day's High
$105.24
Day's Low
$102.70
Volume
4,666,676
Avg. Vol
4,313,703
52-wk High
$128.39
52-wk Low
$93.05

Latest Key Developments (Source: Significant Developments)

Mylan launches generic vidaza injection
Thursday, 2 Jun 2016 07:52am EDT 

Mylan NV : Mylan launches generic vidaza injection .Mylan NV says U.S. Launch of azacitidine for injection, 100 mg/vial, which is a generic version of Celgene's vidaza injection, 100 mg/vial.  Full Article

TriNetX enters into collaboration with celgene to advance clinical trial design and research for next-generation medicines
Tuesday, 24 May 2016 01:00pm EDT 

TriNetX :Announced collaboration with celgene corp to advance clinical trial design and research for celgene's next-generation therapeutic programs.  Full Article

Agios Pharmaceuticals, Celgene establish new collaboration in metabolic immuno-oncology
Tuesday, 17 May 2016 04:01pm EDT 

Agios Pharmaceuticals Inc : Agios and Celgene establish new collaboration in metabolic immuno-oncology and amend certain rights from 2010 agreement . Agios to receive $200 million upfront payment . Ag-120 rights outside United States transferred to Agios . Companies modified certain rights from their 2010 collaboration . As of August 15, 2016, neither party will have financial or other obligations to each other related to AG-120 . After expiration of discovery phase of 2010 agreement, other cancer metabolism programs discovered at co will remain owned by co .Exploratory research, drug discovery and early development will be led by Agios.  Full Article

Celgene Corp appoints Mark Alles CEO, effective March 1, 2016
Thursday, 11 Feb 2016 07:30am EST 

Celgene Corp:Effective March 1, 2016, Mark Alles will be promoted to chief executive officer, with Bob Hugin assuming the executive chairman role.  Full Article

Celgene Corp expands eight-year technology relationship with Medidata Solutions Inc
Wednesday, 10 Feb 2016 06:30am EST 

Medidata Solutions Inc:Celgene expands relationship with Medidata in enterprise clinical trial technology.Says Celgene Corporation expanded its eight-year technology relationship with Medidata.  Full Article

Celgene Corp announces leadership changes
Monday, 11 Jan 2016 11:06am EST 

Celgene Corp:Organizational changes strengthen leadership team and position Celgene for long-term growth.Says Mark Alles to be promoted to Chief Executive Officer.Says Bob Hugin to continue to lead strategic direction of company in the role of Executive Chairman.Says Jacqualyn Fouse, to be promoted to President & Chief Operating Officer.Says Scott Smith, President immunology & inflammation, will assume an expanded leadership role.Says alles has been with Celgene since 2004, most recently serving as president & COO.  Full Article

Inception IBD Inc and Celgene Corp enter strategic collaboration to advance novel therapeutics for inflammatory bowel disease
Thursday, 10 Dec 2015 08:00am EST 

Inception IBD Inc:Co and Celgene enter strategic collaboration to advance novel therapeutics for inflammatory bowel disease.under terms, Inception ibd is eligible to receive up to US$40 million in cash payments during the course of the collaboration.  Full Article

Celgene in Collaboration with Astrazeneca Announce Initiation of Fusion Clinical Development Program in Immuno-Oncology
Monday, 7 Dec 2015 07:30am EST 

Celgene Corp and AstraZeneca:Announced the initiation of the FUSION clinical development program of durvalumab (MEDI4736), an investigational human monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) in hematologic disorders.FUSION program is part of a strategic collaboration with AstraZeneca and its global biologics research and development arm MedImmune, to develop and commercialize durvalumab across a range of blood cancers including non-Hodgkin's lymphoma, myelodysplastic syndromes and multiple myeloma.  Full Article

Celgene Corporation and Acceleron Pharma Inc announces FDA granted Fast Track Designation to luspatercept for treatment of anemia
Monday, 7 Dec 2015 07:00am EST 

Celgene Corporation and Acceleron Pharma Inc:Announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to luspatercept for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (MDS).Fast Track program of the FDA is designed to facilitate the development, and expedite the review, of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.  Full Article

Celgene VIDAZA (Azacitidine for Injection) approved by European Commission as new treatment for elderly patients with acute myeloid leukaemia
Friday, 30 Oct 2015 03:00am EDT 

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation:Says that European Commission (EC) has approved VIDAZA (azacitidine for injection) for the treatment of adult patients aged 65 years or older with acute myeloid leukaemia (AML) who are not eligible for haematopoietic stem cell transplantation (HSCT).Says VIDAZA Marketing Authorisation has been updated to include this new indication in AML, covering patients who have >30% myeloblasts according to the WHO classification; previously, the indication covered AML patients with <30% blasts.  Full Article

Photo

Amgen's multiple myeloma drug falls short in new-patient study

Amgen Inc said on Tuesday its multiple myeloma drug, Kyprolis, did not fare better than Takeda Pharmaceutical Co Ltd's older therapy Velcade in a study involving patients who had not yet been treated for the disease.